Hypoxia Selectively Increases a SMAD3 Signaling Axis to Promote Cancer Cell Invasion

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Signaling

Background:

• Transforming growth factor β (TGFβ) has a dual role in cancer, initially inhibiting then promoting tumor progression, complicating targeted therapies.
• The downstream effectors SMAD2 and SMAD3 have distinct and overlapping functions, and their activation ratio may influence TGFβ's dual role.
• Mechanisms driving selective SMAD activation remain unclear, hindering therapeutic development.

Purpose of the Study:

• To investigate the mechanisms by which hypoxia selectively activates the pro-invasive TGFβ signaling pathway.
• To elucidate the role of SMAD3, SARA, and HDAC6 in hypoxia-induced cancer cell invasion.
• To evaluate the therapeutic potential of selectively inhibiting the SMAD3 pathway in cancer.

Main Methods:

• Experimental investigation of SMAD3 interaction with SMAD-Anchor for Receptor Activation (SARA) under hypoxic conditions.
• Assessment of HDAC6-dependent SMAD3 bioavailability and SARA recruitment to endosomes.
• Analysis of motility gene expression (ITGB2, VIM) and its association with hypoxia-induced invasion.
• Evaluation of therapeutic efficacy using CAM xenograft assays with selective SMAD3 inhibition versus global TGFβ inhibition.

Main Results:

• Hypoxia selectively enhances SMAD3 interaction with SARA, promoting pro-invasive TGFβ signaling.
• HDAC6-dependent SMAD3 bioavailability and increased SARA recruitment to EEA1+ endosomes are crucial for this process.
• SMAD3 selectively upregulates ITGB2 and VIM expression, genes linked to hypoxia-induced invasion, tumor progression, and metastasis.
• Selective inhibition of the SMAD3 pathway significantly reduces tumor progression in xenograft models, outperforming global TGFβ inhibition.

Conclusions:

• Hypoxia drives cancer invasion through a selective HDAC6-SARA-SMAD3 signaling axis.
• Targeting the pro-invasive SMAD3 pathway offers a more effective therapeutic strategy than broad TGFβ inhibition.
• Fine-tuning the HDAC6-SARA-SMAD3 axis presents a promising avenue for developing novel cancer treatments.